RedHill Biopharma's opaganib demonstrates strong inhibition of COVID-19 Delta variant
Opaganib demonstrated strong inhibition of COVID-19 Delta variant in a human bronchial epithelial cell model
Opaganib demonstrated strong inhibition of COVID-19 Delta variant in a human bronchial epithelial cell model
The drug candidate was associated with a reduction in the need for supplemental oxygen support, earlier time to discharge from hospital and was well tolerated
The two patents protect opaganib and RHB-107 for the treatment of COVID-19 until at least 2041 once granted
Opaganib demonstrated dual anti-inflammatory and antiviral activity and targets a human cell component involved in viral replication
RHB-107 is a novel serine protease inhibitor targeting human cell factors involved in viral entry, and is therefore expected to be effective against emerging viral variants with mutations in the spike protein
The randomized, double-blind, placebo-controlled study aims to enroll up to 40 patients with moderate-to-severe COVID-19 pneumonia in the U.S
Proposed study intended to evaluate the safety and efficacy of opaganib in up to 60 patients hospitalized with positive SARS-CoV-2 infection and pneumonia in the U.S.